Blue Rubber Bleb Nevus Syndrome (Bean Syndrome): Comprehensive Disease Characteristics Report

Disease: Blue Rubber Bleb Nevus Syndrome (BRBNS) · MONDO: 0007203 · OMIM: #112200 · Orphanet: ORPHA:2802 Category: Venous malformation syndrome / somatic TEK-TIE2 mosaic vascular anomaly

Summary

Blue Rubber Bleb Nevus Syndrome (BRBNS), also called Bean syndrome, is a rare, congenital, and almost always sporadic multifocal venous malformation (VM) disorder. Its defining feature is the coexistence of characteristic cutaneous venous malformations — soft, blue-violaceous, rubbery, compressible "blebs" with a predilection for the palms and soles — and pathognomonic multifocal gastrointestinal (GI) venous malformations, predominantly of the small bowel. GI lesions bleed chronically, producing recurrent, often transfusion-dependent iron-deficiency anemia that is the principal driver of morbidity and, rarely, mortality.

Molecularly, BRBNS is caused by post-zygotic somatic mosaic activating mutations in TEK (the gene encoding the endothelial receptor tyrosine kinase TIE2). The multifocal forms are distinctively driven by double (cis) mutations — two somatic mutations on the same allele — with T1105N–T1106P recurrent in BRBNS. These mutations cause ligand-independent (constitutive) TIE2 activation, which signals through the PI3K-AKT-mTOR axis to suppress endothelial apoptosis and, via AKT/FOXO1-mediated downregulation of PDGFB, impair pericyte/smooth-muscle recruitment. The result is dilated, ectatic, mural-cell-poor venous channels that enlarge over time and bleed. Venous stasis within lesions produces localized intravascular coagulopathy (LIC), detectable as elevated D-dimer (± low fibrinogen), which serves as a highly specific diagnostic biomarker and complication marker.

This mechanistic understanding directly informs management, which is stratified by lesion burden: conservative iron supplementation and transfusion; endoscopic therapies (sclerotherapy, band ligation, hot-snare polypectomy, cyanoacrylate glue) for accessible lesions; surgical/wedge resection for focal high-burden bowel disease; and systemic mTOR inhibition with sirolimus for diffuse or unresectable disease, which prospectively reduces lesion size, raises hemoglobin, and reduces transfusion dependence. Emerging genotype-guided approaches include the PI3Kα inhibitor alpelisib and preclinical combinations (rapamycin + alpelisib; ponatinib + rapamycin). Model systems — HUVEC-TIE2-L914F xenografts, patient-derived VM endothelial cells, an endothelium-specific zebrafish model, and a genetic mosaic TIE2 p.L914F mouse — faithfully recapitulate the histology and permit therapeutic testing.

This report synthesizes 17 confirmed findings, 11 supported hypotheses, and 83 reviewed papers across all 15 requested disease-characteristic sections.

Key Findings

1. Disease Information

BRBNS (Bean syndrome) is a rare, severe disorder characterized by numerous cutaneous and internal venous malformations, with GI lesions being pathognomonic. The eponym "Bean syndrome" honors William Bennett Bean (1958); the lesions were first described by Gascoyen in 1860. As established by Soblet et al. (2017), "Blue rubber bleb nevus syndrome (Bean syndrome) is a rare, severe disorder of unknown cause, characterized by numerous cutaneous and internal venous malformations" (PMID: 27519652).

Key identifiers (Finding F017):

Synonyms: Bean syndrome; blue rubber bleb naevus syndrome; BRBN syndrome. Within the ISSVA (International Society for the Study of Vascular Anomalies) framework, BRBNS is classified as a multifocal venous malformation (a malformation, not a tumor). Evidence is aggregated disease-level (OMIM/Orphanet/MeSH curated) plus individual-patient case reports and small cohorts; there is no large EHR-derived dataset.

2. Etiology

Primary cause — genetic, somatic, mosaic. BRBNS is caused by somatic activating mutations in TEK (TIE2) (Finding F001). Soblet et al. identified somatic TEK mutations in 15 of 17 individuals with BRBNS and 5 of 6 sporadic multifocal VM patients: "We discovered somatic mutations in TEK, the gene encoding TIE2, in 15 of 17 individuals with blue rubber bleb nevus syndrome" (PMID: 27519652). The multifocal forms are "predominantly caused by double (cis) mutations, that is, two somatic mutations on the same allele of the gene."

Genetic risk factors. The causal driver is the somatic TEK double-cis mutation itself; T1105N–T1106P is recurrent in BRBNS, whereas Y897C–R915C recurs in sporadic multifocal VM. Both "cause ligand-independent activation of TIE2." A rare autosomal dominant familial venous malformation form maps to chromosome 9p (Finding F004; Gallione et al. 1995, PMID: 7783168) — the same region that contains TEK — and BRBNS was proposed as "a particular manifestation of this form of familial venous malformations."

Environmental / lifestyle / infectious risk factors: None identified. BRBNS is a genetically determined mosaic disorder; no toxin, radiation, occupational exposure, diet, or infectious agent has been implicated. There are no known protective factors or gene–environment interactions. This is best recorded as "not applicable for this disease."

3. Phenotypes

Cutaneous morphology (Finding F009): three classic types — large cavernous masses; blue-violaceous dome/nipple-shaped rubbery compressible nodules (0.5–2 cm) that empty and refill; and irregular blue macules — with palm and sole predilection. Becq et al.: "Blue rubber bleb naevus syndrome is characterized by multifocal rubbery cutaneous venous malformations, especially on palm and sole, that are associated with multiple gastrointestinal VM" (PMID: 26564083).

GI is the morbidity-defining phenotype (Finding F010). Soblet: "gastrointestinal lesions are pathognomonic" (PMID: 27519652). GI lesions "are more prone to bleeding than cutaneous lesions and may lead to chronic transfusion-dependent anemia" (PMID: 42542774).

CNS involvement (Finding F009): Rare and late, presenting as cerebral-cavernous-malformation (CCM)-like lesions, seizures, and focal deficits from compression, with rare fatal intracranial hemorrhage. BRBNS is low/mixed-flow, conferring "lower CNS hemorrhagic risk but increased thrombotic complications" (PMID: 41704211); CNS manifestations "are rare, variable, non-specific, and tend to occur late in the disease" (PMID: 32318009).

Severity/progression: Variable severity; progressive and lifelong; lesions enlarge over time. Quality of life is impacted chiefly through chronic anemia (fatigue), recurrent bleeding, pain, transfusion dependence, and, less often, surgical complications; sirolimus improves QoL and coagulation measures (F003).

4. Genetic / Molecular Information

Causal gene: TEK (TIE2), HGNC:11724, NCBI Gene 7010, locus 9p21.2 (Findings F001, F017).

Variant characteristics (Findings F001, F011): - Type/class: Missense, activating. - Architecture: Distinctive double (cis) mutations in multifocal/BRBNS forms — two somatic missense changes on the same allele. T1105N–T1106P recurrent in BRBNS; Y897C–R915C recurrent in sporadic multifocal VM; L914F is the single most common VM driver overall. - Somatic vs germline: Somatic/post-zygotic (mosaic) — identical in all lesions of a given individual, absent from blood in classic cases; low variant allele frequency (often <5%). - Functional consequence: Gain of function — ligand-independent (constitutive) TIE2 autophosphorylation and downstream signaling. - Allele frequency: Not present in population databases as germline variants (somatic driver events).

An illustrative case (PMID: 41327934) found two somatic TEK variants (Y897C, R918H) existing both as single and as double variants in cis, restricted to lesion tissue and absent in blood — a genetic profile consistent with BRBNS and representing an intermediate phenotype between BRBNS and sporadic multifocal VM.

Modifier genes / epigenetics / chromosomal abnormalities: No established modifier genes, no disease-specific epigenetic signature, and no recurrent large-scale chromosomal abnormality are documented for BRBNS. The chromosome 9p familial linkage (F004) reflects the TEK locus, not an independent structural lesion. A single case reported a novel PDGFRA variant with comorbid ASD (PMID: 42650349), but this is not an established modifier.

5. Environmental Information

Not applicable. No environmental toxins, radiation, pollution, occupational exposure, lifestyle factor, or infectious agent has been implicated in the causation or triggering of BRBNS. The disorder is fully explained by somatic mosaic TEK activation.

6. Mechanism / Pathophysiology

Ordered causal chain (Finding F011, F002, F007):

1. A somatic double (cis) activating TEK/TIE2 mutation arises post-zygotically in an endothelial-lineage cell (mosaic; T1105N–T1106P recurrent in BRBNS) — leads to →
2. Ligand-independent (constitutive) TIE2 receptor autophosphorylation (demonstrated in vivo; Morris 2005) — results in →
3. Constitutive activation of PI3K (p110α/PIK3CA)–AKT–mTOR signaling (dominant-negative AKT abolishes the pro-survival effect; TIE2 additionally elevates MAPK-ERK) — leads to →
4. Suppression of endothelial apoptosis + increased endothelial survival, invasion, and colony formation; inhibition of normal angiogenesis — and in parallel →
5. AKT/FOXO1 axis downregulates PDGFB in mutant endothelial cells — results in →
6. Reduced pericyte / smooth-muscle-cell (α-SMA) recruitment to the vessel wall — leads to →
7. Dilated, ectatic, smooth-muscle-poor venous channels that expand over time and bleed (clinical VM); within them, venous stasis — results in →
8. Localized intravascular coagulopathy (LIC) — chronic consumptive coagulopathy with elevated D-dimer ± low fibrinogen (branch to coagulation complications).

Branch points: (a) the PI3K-AKT-mTOR branch drives cell survival and lesion growth; (b) the AKT/FOXO1→PDGFB branch drives the mural-cell deficiency; (c) the stasis→LIC branch drives coagulopathy. mTOR inhibition (rapamycin) acts on branches (a)/(b) — it suppresses mutant-induced AKT signaling and restores FOXO1 nuclear localization/PDGFB. Steps 1–4 are directly demonstrated; step 5–6 (PDGFB/mural-cell link) is demonstrated in TIE2-L914F veins/models; step 7–8 (stasis→LIC) is inferred from lesion hemodynamics plus consistent biomarker data.

Supporting quotes: - "multifocal forms are predominantly caused by double (cis) mutations" and "both cause ligand-independent activation of TIE2, and increase survival, invasion, and colony formation when expressed in human umbilical vein endothelial cells" (PMID: 27519652). - "The anti-apoptotic kinase Akt was constitutively activated in cells expressing mutant receptor. Dominant-negative Akt inhibited the pro-survival activity of mutant Tie2" (PMID: 15526080). - "this mutation activates the PI3K pathway, promoting cell proliferation, inhibiting normal angiogenesis, and suppressing apoptosis" (PMID: 42411503). - "often caused by somatic PIK3CA mutations that hyperactivate the PI3Kα-AKT-mTOR signaling pathway" (PMID: 40410415). - "VMs with TIE2-L914F mutation showed lower expression of PDGFB and α-SMA than normal veins" (PMID: 32867785).

Ontology suggestions: GO:0043491 (PI3K-Akt signaling), GO:0038084 (VEGF/angiopoietin-receptor signaling), GO:0043066 (negative regulation of apoptotic process), GO:0001525 (angiogenesis), GO:0007596 (blood coagulation). Cell types: CL:0000115 (endothelial cell), CL:0002543 (vein endothelial cell), CL:0000669 (pericyte), CL:0000192 (smooth muscle cell). Molecular pathways: PI3K-AKT-mTOR (upstream driver), MAPK-ERK (secondary), angiopoietin-TIE2 feedforward circuit (PMID: 40410415).

7. Anatomical Structures Affected

• Primary organs: Skin (dermis/subcutis) and gastrointestinal tract (small bowel > colon > stomach; also esophagus, oral mucosa to anal canal). Multi-organ involvement includes liver and lung (PMID: 40074320: "venous malformations in multiple organs, including the skin, gastrointestinal tract, liver, and lungs").
• Secondary/complication sites: CNS (rare, late, CCM-like), spinal epidural space (cord compression), airway/larynx/trachea (rare fatal hemorrhage), skeletal muscle, mediastinum.
• Body systems: Integumentary, digestive, cardiovascular (venous), hematologic (coagulation), rarely nervous/respiratory.
• Tissue/cell level: Endothelial-lined ectatic venous channels with scarce smooth-muscle-cell coverage; affected cell populations are venous endothelial cells (CL:0002543) with deficient pericytes/SMCs (CL:0000669 / CL:0000192).
• Subcellular: Endothelial plasma-membrane receptor (TIE2), cytoplasmic PI3K-AKT-mTOR signaling machinery, nucleus (FOXO1 localization). GO cellular components: GO:0005886 (plasma membrane), GO:0005634 (nucleus).
• UBERON localization: UBERON:0002097 (skin), UBERON:0002108 (small intestine), UBERON:0000160 (intestine), UBERON:0002107 (liver), UBERON:0002048 (lung). Lateralization: typically bilateral/multifocal/disseminated; occasional unilateral/segmental reports.

8. Temporal Development

Onset: Congenital (F014). BRBNS is "a rare congenital disorder" (PMID: 42301891). Cutaneous VMs frequently present at birth or in infancy; GI lesions typically declare later via chronic bleeding and iron-deficiency anemia. Onset pattern is chronic/insidious.

Diagnosis: Median age at diagnosis 12 years in the largest cohort (Becq 2025, n=44) — "BRBNS is diagnosed at a median age of 12 years, mainly based on clinical presentation (65.9%)" (PMID: 39426903). Late/adult-onset diagnoses occur (68-year-old, PMID: 42369626; 83-year-old, PMID: 42542774; 79-year-old, PMID: 39557791).

Progression: Lifelong and progressive — lesions enlarge over time; LIC worsens with lesion burden and age. Course is chronic rather than relapsing-remitting, punctuated by episodic bleeding events. Remission is treatment-induced (endoscopic/surgical/sirolimus), not spontaneous. Critical intervention window: early recognition of GI disease to prevent anemia and avert emergency surgical complications (intussusception, volvulus, infarction).

9. Inheritance and Population

Epidemiology: BRBNS is rare (<1000 cases historically reported; ~200 detailed case reports through the mid-2020s). General-population VM prevalence is ~1% (Shiraishi 2026, PMID: 41721464), but BRBNS itself is far rarer; precise prevalence/incidence figures are not established.

Inheritance (F004, F014): Nearly all cases are sporadic (somatic mosaic) and non-inherited. Rare autosomal dominant familial venous malformation kindreds map to chromosome 9p (Gallione 1995, PMID: 7783168); older reports describe autosomal dominant inheritance with good penetrance (PMID: 6662253, PMID: 3732758). For the somatic-mosaic majority, classical Mendelian penetrance/expressivity/anticipation concepts do not apply; expressivity across lesions within a patient is uniform (identical mutation in all lesions).

Germline mosaicism / founder effects / consanguinity / carrier frequency: Not established; the disorder is somatic and not associated with founder effects or consanguinity.

Demographics: No strong ethnic predilection; reported worldwide. Sex ratio is approximately equal (no consistent male:female skew). Age distribution: diagnosis clusters in childhood (median ~12 y) but spans neonates to the ninth decade.

10. Diagnostics

Clinical/laboratory tests: - CBC / iron studies: iron-deficiency anemia, often severe (Hb as low as 5 g/dL reported). - Coagulation biomarker — D-dimer (Finding F013): elevated D-dimer (± low fibrinogen) is a highly specific biomarker of VMs, including syndromic forms. Dompmartin 2009 (n=280): D-dimer sensitivity 42.6%, specificity 96.5% for VMs — "Elevated D-dimer level is highly specific for VMs (pure, combined, or syndromic)... this easy and inexpensive biomarker test should become part of the clinical evaluation of vascular anomalies" (PMID: 19917952). D-dimer distinguishes VM (elevated) from glomuvenous and lymphatic malformation (normal). Local lesional blood shows markedly higher TAT/PIC/FDP/D-dimer than paired peripheral blood (PMID: 42557218). LIC is "a consumptive coagulopathy characterised by elevated D-dimer and decreased fibrinogen levels" (PMID: 28169477).

Imaging: - MRI (fat-suppressed T2) is the cornerstone: VMs show markedly high T2 signal; enables whole-body multifocal assessment (PMID: 18414932). - Ultrasound/Doppler for flow characterization (low-flow lesions). - Brain MRI screening advised given possible cerebral VM (PMID: 26564083).

Endoscopy (critical for GI diagnosis): Video capsule endoscopy is the most sensitive modality for small-bowel lesions; double-balloon / intraoperative enteroscopy for localization and therapy (PMID: 34976762, PMID: 41952941).

Histopathology: Dilated, thin-walled venous channels lined by endothelium (CD31+) with scant smooth muscle; myxoid degeneration/clot in walls.

Genetic testing (Finding F007): Because driver variants occur at low VAF (<5%), standard blood testing is often negative. Ultra-deep NGS of lesional tissue achieves high molecular diagnosis rates (Zhang 2023: 79.1% in 67 pediatric VM patients; TEK L914F predominant — "The hotspot GNAQ p.R183Q and TEK p.L914F mutations were responsible for the majority of port-wine stain/Sturge-Weber syndrome and venous malformation, respectively" — PMID: 37658401). Liquid biopsy with ultra-deep targeted NGS of cell-free DNA detects variants down to 0.05% VAF using a 5-gene panel (BRAF, KRAS, MAP2K1, PIK3CA, TEK/TIE2) — "Ultra-deep NGS (mean coverage: 104,000×) with unique molecular identifier error correction was performed using a custom panel of five genes" (PMID: 41417427). WGS/WES on blood is low-yield; targeted deep sequencing of lesional tissue is the recommended approach.

Clinical criteria & differential diagnosis (Finding F016): Diagnosis rests on the clinical triad of multifocal cutaneous rubbery blebs + multifocal GI VMs + supportive coagulation/genetic findings. Key differentials:

Maffucci is historically misdiagnosed as BRBNS until enchondromata are recognized: "a diagnosis of blue rubber bleb naevus syndrome had been made many years earlier. However, after recognition of the characteristic enchondromata, this diagnosis has been revised to Maffucci's syndrome" (PMID: 15670176). D-dimer "can detect hidden VMs and help differentiate glomuvenous malformation (normal D-dimer levels) from other multifocal venous lesions" (PMID: 19917952).

Screening: No newborn or carrier screening (somatic disorder). Cascade screening not applicable to the sporadic majority.

11. Outcome / Prognosis

Survival/mortality: Generally compatible with normal life expectancy with appropriate management. Fatal outcomes are exceedingly rare and result from acute hemorrhage — GI, CNS (neonatal brain bleed, PMID: 26608350), or airway (fatal tracheostomy-site hemorrhage, PMID: 41557089).

Morbidity: Dominated by chronic transfusion-dependent iron-deficiency anemia and its sequelae (fatigue, reduced function). GI bleeding is the most common complication (54.3% in the 44-patient cohort, requiring endoscopic treatment in 36.4% — PMID: 39426903).

Complications: Recurrent GI hemorrhage; intussusception, volvulus, intestinal infarction, bowel obstruction requiring emergency surgery (PMID: 32664167, PMID: 28946166); epidural spinal cord compression (PMID: 25238626); perioperative hemorrhage/DIC (PMID: 28858742); thrombotic complications from LIC. Rare malignant complication — esophageal squamous carcinoma (PMID: 42050915, PMID: 42116360).

Prognostic factors: Lesion burden (number/size/tissue planes) correlates with LIC severity and bleeding; small-bowel-predominant disease predicts refractory bleeding needing surgery. Prognostic biomarker: D-dimer/LIC severity tracks lesion burden and treatment response (PMID: 28169477, PMID: 29221638).

12. Treatment

Burden-stratified strategy (Findings F003, F008, F010, F012):

Supportive/conservative: Iron supplementation and blood transfusion for anemia (mainstay for low-burden disease). NCIT: Iron Supplement Therapy; Blood Transfusion.

Endoscopic (accessible GI lesions): Sclerotherapy (e.g., lauromacrogol), band ligation, hot-snare/polypectomy, argon plasma coagulation, cyanoacrylate glue. Effective for focal, reachable lesions; cyanoacrylate carries rare ischemic complications (PMID: 38770491). NCIT: Endoscopic Sclerotherapy.

Surgical: Wedge/segmental bowel resection for high-burden focal disease; can achieve transfusion independence and Hb normalization (e.g., >100 lesions resected, PMID: 42662159). Emergency surgery for intussusception/volvulus/obstruction. NCIT: Surgical Resection.

Systemic pharmacotherapy — sirolimus (mTOR inhibitor; NCIT: Sirolimus): First-line systemic agent for diffuse/unresectable disease. Prospective study of 11 BRBNS patients (Zhou 2021): "The average lesion size was reduced by 7.4% (P < 0.001), 9.3% (P < 0.001), and 13.0% (P < 0.05) at 3, 6, and 12 months of sirolimus treatment, respectively. Hemoglobin increased significantly after 6- and 12-month treatment (P = 0.006 and 0.019, respectively)" (PMID: 33416235); only 1/11 required transfusion during study, with only grade 1–2 adverse effects. Pooled pediatric series (28 cases) all responded (PMID: 32933636). Phase II trial in complicated vascular anomalies (NCT00975819, n=61): at course 6, of 57 evaluable, "a total of 47 patients had a partial response, 3 patients had stable disease, and 7 patients had progressive disease", no complete responses; grade ≥3 blood/bone-marrow toxicity 27% (PMID: 26783326). Topical/gel and intralesional (direct-stick) mTOR-inhibitor formulations are emerging (PMID: 37649426, PMID: 39515753).

Targeted/emerging (Finding F012): - Alpelisib (BYL719, PI3Kα inhibitor): "The p110α-specific inhibitor BYL719 restores all abnormal phenotypes tested, in PIK3CA- as well as TEK-mutant HUVECs" (PMID: 26637981); emerging for PIK3CA-mutated malformations (PMID: 32557381). - Rapamycin + alpelisib combination: superior in TIE2-L914F models — "the combination of rapamycin and alpelisib exhibited superior therapeutic efficacy, not only significantly inhibiting the PI3K pathway but also activating P53 expression" (PMID: 42411503). - Ponatinib + rapamycin: "Combination treatment with the ABL kinase inhibitor ponatinib and rapamycin caused VM regression in a xenograft model" (PMID: 30626204).

Treatment strategy: Escalate from supportive → endoscopic → surgical → systemic (sirolimus) → targeted, guided by lesion number, location, resectability, and bleeding severity. Combination of systemic sirolimus + endoscopic sclerotherapy has documented efficacy — "The combination of oral sirolimus with endoscopic lauromacrogol has demonstrated efficacy in reducing lesion size and elevating hemoglobin levels" (PMID: 39867693). No pharmacogenomic dosing standard specific to BRBNS.

13. Prevention

Primary prevention: Not possible — BRBNS is a congenital somatic mosaic disorder with no modifiable risk factors and no vaccine target.

Secondary prevention (early detection): Consider BRBNS in any child/adult with unexplained iron-deficiency anemia + bluish compressible cutaneous nodules; early capsule endoscopy and MRI enable early GI diagnosis before severe anemia/complications. Brain MRI screening is advised for possible cerebral VM (PMID: 26564083).

Tertiary prevention (complication avoidance): Routine D-dimer/fibrinogen monitoring for LIC (underused — done in <50% of the cohort); perioperative anticoagulation/LMWH for LIC; careful peri-procedural planning to avoid catastrophic hemorrhage (airway, delivery). Surveillance of enlarging lesions; iron repletion to prevent chronic anemia.

Genetic counseling: For the sporadic majority, recurrence risk is negligible; counsel that the disorder is somatic/non-inherited. For rare familial 9p/germline TEK kindreds, autosomal dominant counseling applies.

14. Other Species / Natural Disease

• Taxonomy: BRBNS as a defined syndrome is a human disorder (NCBI Taxon 9606). No naturally occurring BRBNS is documented in companion animals or wildlife (no OMIA equivalent entry).
• Orthologous gene: Tek/Tie2 is highly conserved — mouse Tek (NCBI Gene 21687), zebrafish tek — enabling model organisms.
• Comparative biology: TIE2 signaling and its role in venous development are evolutionarily conserved, which underlies faithful zebrafish and mouse modeling (below). No zoonotic potential (non-infectious).

15. Model Organisms

Cellular / in vitro (Findings F005, F015): HUVEC-TIE2-L914F and patient-derived VM endothelial cells (harboring TIE2, PIK3CA, or combined mutations) show constitutive AKT (TIE2 additionally MAPK-ERK), enhanced survival/motility, and decreased tube formation (PMID: 29786783, PMID: 32867785).

Xenograft mouse (mammalian in vivo): HUVEC-TIE2-L914F or VM-EC injected subcutaneously into immune-deficient mice form ectatic vascular channels recapitulating VM histopathology within 7–9 days — "human umbilical vein endothelial cells (HUVEC) expressing a constitutive active form of the endothelial tyrosine kinase receptor TEK (TIE2 p.L914F) or patient-derived EC" (PMID: 32754818); "VM-EC implanted into immune-deficient mice generated lesions with ectatic blood-filled channels with scarce smooth muscle cell coverage, similar to patients' VM" (PMID: 29786783). Used to demonstrate rapamycin efficacy vs ineffective TIE2-TKI (PMID: 26258417), ponatinib+rapamycin regression (PMID: 30626204), and rapamycin+alpelisib synergy (PMID: 42411503).

Genetic mosaic knock-in mouse (NEW): Bischoff 2026 — "constitutive, mosaic expression of TIE2 p.L914F during mouse development causes venous malformation"; "While germline or early developmental expression of this mutation is thought to be lethal, mosaic or somatic expression is expected to result in VM disease" (PMID: 42059767). This directly models the human somatic-mosaic mechanism and confirms mosaicism (not germline) is required.

Zebrafish (Finding F006): Endothelium-specific overexpression of patient-derived TEK variants robustly induces VMs; double (cis) TEK mutations have an additive effect vs single variants, and sirolimus abrogates VM development — "double mutations have an additive effect in inducing VMs compared with the respective single variants. The clinically established mTOR-inhibitor sirolimus (rapamycin) efficiently abrogates the development of VMs in this zebrafish model" (PMID: 34254124). The assay also functionally classifies TEK variants of unknown significance (VUS).

Phenotype recapitulation: High — models reproduce ectatic, mural-cell-poor venous channels and sirolimus responsiveness. Limitations: Xenograft/overexpression models may not capture chronic multi-organ GI bleeding, LIC natural history, or lesion evolution over a human lifetime; germline TIE2-L914F is embryonically lethal, necessitating mosaic strategies.

Mechanistic Model / Interpretation

 SOMATIC double-cis TEK/TIE2 mutation (post-zygotic, mosaic; T1105N-T1106P)
     │  gain of function
     ▼
   Ligand-independent (constitutive) TIE2 autophosphorylation
     │
     ▼
PI3K (p110α) ── AKT ── mTOR   (± MAPK-ERK secondary)
      │                   │
    ┌─────────┘                   └───────────────┐
    ▼                                             ▼
 AKT/FOXO1 ↓PDGFB                     ↓apoptosis / ↑survival, invasion
    │                                             │
    ▼                                             ▼
 ↓pericyte/SMC (α-SMA) recruitment      endothelial expansion
    └───────────────┬─────────────────────────────┘
    ▼
     DILATED, ECTATIC, SMOOTH-MUSCLE-POOR VENOUS CHANNELS
(skin blebs + pathognomonic GI VMs; liver, lung, rare CNS)
    │
      ┌─────────────┼───────────────────────────┐
      ▼             ▼                           ▼
  chronic GI    venous stasis →           lesion growth
  bleeding      LOCALIZED INTRAVASCULAR    over lifetime
      │         COAGULOPATHY (↑D-dimer)         │
      ▼             │                           ▼
 transfusion-dep.   └── thrombosis / rare DIC   progressive
 iron-def. anemia                                disease

  THERAPEUTIC NODES:
   • mTOR inhibition (SIROLIMUS) ── blocks mTOR, restores FOXO1/PDGFB
   • PI3Kα inhibition (ALPELISIB) ── blocks upstream driver
   • Combinations (rapamycin+alpelisib; ponatinib+rapamycin) ── synergy

The model is internally consistent and links every clinical feature to the initiating somatic lesion: the double-cis TEK mutation explains the multifocality and BRBNS-specific recurrence; PI3K-AKT-mTOR explains sirolimus/alpelisib efficacy; AKT/FOXO1→PDGFB loss explains the histologic hallmark (mural-cell-poor ectatic veins); stasis→LIC explains the D-dimer biomarker and coagulopathic/thrombotic complications; and GI lesion fragility explains the dominant morbidity (bleeding/anemia).

Evidence Base

The evidence is coherent and mutually reinforcing across human clinical (cohorts, case series, prospective/Phase II trials), model organism (mouse xenograft, mosaic knock-in, zebrafish), and in vitro (HUVEC/VM-EC) sources. No study in the reviewed corpus contradicts the core TEK→PI3K-AKT-mTOR model; the main tension is between the somatic-mosaic majority and rare familial autosomal-dominant kindreds, which is reconciled by both involving the TEK/9p locus.

Supported and Refuted Hypotheses

All 11 formally tracked hypotheses were supported; none were refuted.

Limitations and Knowledge Gaps

1. Epidemiology is imprecise. No reliable population prevalence/incidence for BRBNS specifically; estimates rest on ~200 detailed case reports and small cohorts (largest n=44). No large EHR or registry dataset exists.
2. Genotype under-tested clinically. In the largest cohort, D-dimer, fibrinogen, and TEK testing were used in <50% of patients; low-VAF variants require specialized deep sequencing not universally available.
3. No randomized controlled trials of sirolimus in BRBNS specifically; evidence is prospective single-arm/observational and pooled pediatric series. Optimal dose, duration, and long-term safety (especially in children) remain undefined; rebound on cessation is reported.
4. Targeted therapy data are preclinical for alpelisib and combination regimens in TEK-driven disease; human efficacy in BRBNS is not yet established.
5. Natural history quantification is limited — progression rate, lifetime bleeding trajectory, and predictors of the rare malignant complication (esophageal carcinoma) are poorly characterized.
6. Model limitations — xenograft/overexpression systems do not reproduce chronic GI bleeding/LIC natural history; the mosaic mouse is new and its phenotypic fidelity to human multi-organ disease needs further characterization.
7. Modifier genes and epigenetics of BRBNS are essentially unstudied.

Proposed Follow-up Experiments / Actions

1. Establish a BRBNS registry capturing genotype (deep lesional sequencing), lesion distribution, D-dimer/fibrinogen, treatment, and outcomes to derive prevalence, natural history, and prognostic models.
2. Standardize molecular diagnosis: validate liquid-biopsy ultra-deep NGS (cfDNA, 5-gene panel) against lesional sequencing as a minimally invasive diagnostic across a BRBNS cohort; define VAF thresholds for GI-burden correlation.
3. Prospective/randomized sirolimus trial in BRBNS with standardized endpoints (lesion volume by MRI, hemoglobin, transfusion frequency, D-dimer, QoL), dose optimization, and pediatric long-term safety.
4. First-in-BRBNS trials of alpelisib and rapamycin+alpelisib combination, genotype-guided (TEK vs PIK3CA), leveraging the preclinical synergy and P53-activation signal.
5. Characterize the mosaic TIE2-L914F mouse for GI involvement, bleeding, and LIC, and use it to test intralesional/topical mTOR-inhibitor delivery and combinations.
6. Biomarker qualification: prospectively test whether serial D-dimer predicts bleeding events and treatment response in BRBNS, toward a validated monitoring biomarker.
7. Investigate malignancy risk: systematically assess whether chronic mucosal injury from GI lesions elevates carcinoma risk (esophageal), informing surveillance recommendations.

Report compiled from 17 confirmed findings, 11 supported hypotheses, and 83 reviewed papers over a 10-iteration autonomous investigation. Evidence types span human clinical cohorts/trials, model-organism (mouse, zebrafish), and in vitro endothelial-cell studies.

Artifacts

• OpenScientist final report
• OpenScientist final report

Citations

1. PMID:27519652
2. PMID:7783168
3. PMID:26564083
4. PMID:42542774
5. PMID:41704211
6. PMID:32318009
7. PMID:41327934
8. PMID:42650349
9. PMID:15526080
10. PMID:42411503
11. PMID:40410415
12. PMID:32867785
13. PMID:40074320
14. PMID:42301891
15. PMID:39426903
16. PMID:42369626
17. PMID:39557791
18. PMID:41721464
19. PMID:6662253
20. PMID:3732758
21. PMID:19917952
22. PMID:42557218
23. PMID:28169477
24. PMID:18414932
25. PMID:34976762
26. PMID:41952941
27. PMID:37658401
28. PMID:41417427
29. PMID:15670176
30. PMID:26608350
31. PMID:41557089
32. PMID:32664167
33. PMID:28946166
34. PMID:25238626
35. PMID:28858742
36. PMID:42050915
37. PMID:42116360
38. PMID:29221638
39. PMID:38770491
40. PMID:42662159
41. PMID:33416235
42. PMID:32933636
43. PMID:26783326
44. PMID:37649426
45. PMID:39515753
46. PMID:26637981
47. PMID:32557381
48. PMID:30626204
49. PMID:39867693
50. PMID:29786783
51. PMID:32754818
52. PMID:26258417
53. PMID:42059767
54. PMID:34254124